Nathan H. Fowler, MD - Building Innovative Treatment Options for Patients With B-Cell Malignancies: Practical Insights on Clinical Evidence and Integration Strategies

53:37
 
Share
 

Manage episode 229405246 series 9912
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

261 episodes available. A new episode about every 3 days averaging 58 mins duration .